Shares of BioAmber Inc. (NYSE:BIOA) hit a new 52-week low during trading on Friday . The company traded as low as $0.39 and last traded at $0.39, with a volume of 2,160,971 shares traded. The stock had previously closed at $0.44.

A number of brokerages recently commented on BIOA. ValuEngine lowered BioAmber from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded BioAmber from a “sell” rating to a “hold” rating in a research report on Wednesday, July 26th. Finally, Cowen and Company set a $3.00 target price on BioAmber and gave the stock a “hold” rating in a report on Monday, July 17th.

The stock has a 50-day moving average price of $1.26 and a 200 day moving average price of $2.23. The company’s market cap is $12.53 million.

BioAmber (NYSE:BIOA) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $4.12 million during the quarter, compared to analyst estimates of $4.09 million. BioAmber had a negative net margin of 221.82% and a negative return on equity of 56.55%. On average, equities analysts expect that BioAmber Inc. will post ($0.58) EPS for the current year.

Several large investors have recently modified their holdings of the stock. NN Investment Partners Holdings N.V. bought a new stake in shares of BioAmber during the first quarter valued at $2,548,000. Robecosam AG boosted its stake in shares of BioAmber by 3.1% in the first quarter. Robecosam AG now owns 825,000 shares of the biotechnology company’s stock valued at $1,898,000 after buying an additional 25,000 shares during the last quarter. FMR LLC boosted its stake in shares of BioAmber by 18.7% in the first quarter. FMR LLC now owns 1,335,000 shares of the biotechnology company’s stock valued at $3,097,000 after buying an additional 210,000 shares during the last quarter. Sabby Management LLC bought a new stake in shares of BioAmber during the first quarter valued at $3,388,000. Finally, TD Asset Management Inc. bought a new stake in shares of BioAmber during the second quarter valued at $977,000. 37.40% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/02/bioamber-inc-bioa-sets-new-12-month-low-at-0-39.html.

About BioAmber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.